Looking to sharpen its diagnostic business focus, Hologic has sold a business unit
it acquired when it bought Gen-Probe
in August 2012. Immucor, a manufacturer of reagent instruments for blood transfusions, has agreed to purchase the outstanding shares of Lifecodes from Hologic for $85 million in cash. The transaction includes a contingency payment of $10 million based on financial targets in the 2013 calendar year. Lifecodes sells molecular and antibody-based assays for transplant diagnostics, specialty coagulation, and transfusion medicine.
Based in Norcross, GA, Immucor says the acquisition of Lifecodes will enable the company to offer customers a single testing source for transfusion and transplantation IVDs. The global market for transplantation diagnostics is $400 million and growing, Immucor says. Lifecodes specializes in human leukocyte antigen (HLA) typing and screening in pre-transplant settings for determining patient-donor compatibility. Post-transplant, HLA is used to monitor patients for graft rejection. Immucor’s product line includes two fully automated systems for serology testing.
The transaction is expected to close in the first calendar quarter of 2013, pending customary closing conditions and applicable regulatory approval.